Thimble Point Acquisition Corp.

12/07/2021 | Press release | Distributed by Public on 12/07/2021 16:23

Statement of Changes in Beneficial Ownership (Form 4)

Ownership Submission
FORM 4
Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287Expires:January 31, 2005Estimated average burden hours per response...0.5
1. Name and Address of Reporting Person *
Maricich Yuri
2. Issuer Name and Ticker or Trading Symbol
Pear Therapeutics, Inc. [PEAR]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
Chief Medical Officer /
(Last) (First) (Middle)
C/O PEAR THERAPEUTICS, INC. , 200 STATE STREET, 13TH FLOOR
3. Date of Earliest Transaction (Month/Day/Year)
(Street)
BOSTON MA 02109
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Join/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code 4. Securities Acquired (A) or Disposed of (D) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) 6. Ownership Form: Direct (D) or Indirect (I) 7. Nature of Indirect Beneficial Ownership
Code V Amount (A) or (D) Price
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code 5. Number of Derivative Securities Acquired (A) or Disposed of (D) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security 8. Price of Derivative Security 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) 11. Nature of Indirect Beneficial Ownership
Code V (A) (D) Date Exercisable Expriation Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Maricich Yuri
C/O PEAR THERAPEUTICS, INC.
200 STATE STREET, 13TH FLOOR
BOSTON, MA02109


Chief Medical Officer

Signatures

/s/ Stacie S. Aarestad, Attorney-in-Fact 2021-12-07
**Signature of Reporting Person Date

Explanation of Responses:

(*) If the form is filed by more than one reporting person, see Instruction 5(b)(v).
(**) Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Received in accordance with the terms of the Business Combination Agreement (the "Business Combination Agreement") dated as of June 21, 2021, by and among Thimble Point Acquisition Corp., Oz Merger Sub, Inc. and Pear Therapeutics (US), Inc. (f/k/a Pear Therapeutics, Inc.) ("Private Pear"), in exchange for 50,000 shares of common stock of Private Pear previously held by Mr. Maricich.
(2) 100% of the shares subject to this option are fully vested and exercisable.
(3) Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 50,000 shares of common stock of Private Pear for $0.02 per share.
(4) Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 30,000 shares of common stock of Private Pear for $1.00 per share.
(5) Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 120,000 shares of common stock of Private Pear for $0.20 per share.
(6) Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 70,000 shares of common stock of Private Pear for $1.05 per share.
(7) 25% of the shares underlying the option vested or shall vest on March 14, 2020 and an additional 2.0833 and 1/3% of the shares vested or shall vest on the last day of each calendar month thereafter.
(8) Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 60,000 shares of common stock of Private Pear for $1.58 per share.
(9) 25% of the shares underlying the option vested or shall vest on March 24, 2021 and an additional 2.0833 and 1/3% of the shares vested or shall vest on the last day of each calendar month thereafter.
(10) Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 70,000 shares of common stock of Private Pear for $1.60 per share.
(11) 25% of the shares underlying the option vested or shall vest on January 26, 2022 and an additional 2.0833 and 1/3% of the shares vested or shall vest on the last day of each calendar month thereafter.
(12) Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 150,000 shares of common stock of Private Pear for $1.89 per share.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.